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Summary
 
T cell–dependent humoral immune responses are initiated by the activation of naive B cells in
the T cell areas of the secondary lymphoid tissues. This primary B cell activation leads to mi-
gration of germinal center (GC) cell precursors into B cell follicles where they engage follicular
dendritic cells (FDC) and T cells, and differentiate into memory B cells or plasma cells. Both B
cell migration and interaction with FDC critically depend on integrin-mediated adhesion. To
date, the physiological regulators of this adhesion were unkown. In the present report, we have
identified the c-
 
met
 
–encoded receptor tyrosine kinase and its ligand, the growth and motility
factor hepatocyte growth factor/scatter factor (HGF/SF), as a novel paracrine signaling path-
way regulating B cell adhesion. We observed that c-Met is predominantly expressed on
CD38
 
 
 
CD77
 
 
 
 tonsillar B cells localized in the dark zone of the GC (centroblasts). On tonsil B
cells, ligation of CD40 by CD40-ligand, induces a transient strong upregulation of expression
of the c-Met tyrosine kinase. Stimulation of c-Met with HGF/SF leads to receptor phosphory-
lation and, in addition, to enhanced integrin-mediated adhesion of B cells to both VCAM-1
and fibronectin. Importantly, the c-Met ligand HGF/SF is produced at high levels by tonsillar
stromal cells thus providing signals for the regulation of adhesion and migration within the
lymphoid microenvironment.
 
A
 
ntigen-specific B cell differentiation, the process by
which naive B cells develop into memory cells or
plasma cells, requires multiple interactions of B cells with
other cells, such as T cells and follicular dendritic cells
(FDC)
 
1
 
, and with the extracellular matrix (ECM), that take
place within distinct microenvironmental compartments of
the lymphoid tissues (1–6). After their initial activation in
the extrafollicular T cell (paracortical) area, germinal center
(GC) founder cells migrate into B cell follicles where they
initiate the formation of GCs (7, 8). Once in the germinal
center (GC), the B cells first pass the dark zone where they
undergo rapid clonal expansion and somatic hypermutation
in their IgV genes (9–13). Mutated B cells then progress to
centrocytes and move to the basal light zone of the GC.
Here they reencounter antigen, presented as low levels of
immune complexes on FDC, and undergo affinity selection
(14–16). Whereas low-affinity mutants and autoreactive mu-
tants die by apoptosis, high-affinity mutants internalize anti-
gen and process it on their migration pathway to the apical
light and outer zones of the GC. In these areas, the affinity-
selected B cells present antigen to antigen-specific GC T
cells (17–19). Cognate T–B interaction results in expansion
and Ig isotype switching of high-affinity B cells (20, 21),
that mature into memory B cells or plasma cells and receive
signals mediating their export from the lymphoid organ (1).
Adhesion regulation, particularly regulation of lymphocyte
integrin function, is believed to be fundamental to the con-
trol of cell migration and microenvironmental homing dur-
ing this B cell differentiation process (22, 23).
Integrins are a widespread family of heterodimeric (
 
  
 
)
transmembrane glycoproteins that can function as cell–
ECM and cell–cell adhesion receptors (for review see refer-
ence 24). In the immune system they are involved at multi-
ple levels, including interaction of lymphoid precursors
with stromal cells during lymphopoiesis, lymphocyte hom-
ing, and antigen presentation. Importantly, adhesion recep-
tors of the integrin family have recently been implicated in
B cell differentiation. Integrins, specifically 
 
 
 
4
 
 
 
1, were shown
to be involved in adhesion and terminal differentiation of
 
1
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precursors during B-lymphopoiesis in the bone marrow in
vitro (25, 26), and in B cell adhesion to FDC during GC
reactions (27–29). In vivo experiments with 
 
 
 
4null chi-
meric mice, confirmed a key role for this integrin in early
B cell development (30). Together, these studies indicate
that integrin mediated adhesion plays an important role in
the control of several steps of B cell development, includ-
ing migration and adhesion during antigen-specific differ-
entiation. However, the physiological regulators of lympho-
cyte integrin activity during B cell differentiation remain
unknown.
In a survey of the molecular pathways that might regu-
late B cell adhesion, we explored the possible role of the
c-
 
met
 
-encoded receptor tyrosine kinase and its ligand hepa-
tocyte growth factor/scatter factor (HGF/SF). The HGF/
SF–c-Met pathway has been shown to regulate growth,
motility and morphogenesis of epithelial and endothelial
cells (31–36), which requires tight regulation of adhesion
and de-adhesion. Furthermore, this pathway mediates inva-
sion and migration of tumor cells (37–39), a process remi-
niscent of lymphocyte migration. Here, we identify the
HGF/SF–c-Met pathway as a novel molecular pathway in
antigen-specific B cell differentiation, which is involved in
the regulation of integrin-mediated B cell adhesion.
 
Materials and Methods
 
Antibodies.
 
Mouse monoclonal antibodies used were anti–
c-Met, DO24 (IgG2a) (Upstate Biotechnology, Lake Placid, NY);
anti-CD38, OKT-10 (IgG1) (American Type Culture Collection
[ATCC], Rockville, MD); FITC-conjugated anti-CD38, HIT2
(IgG1) (Caltag Laboratories, Burlingame, CA); biotin-conjugated
anti-CD38, HIT2 (IgG1) (Caltag); anti-
 
 
 
1 integrin (CD29), 4B4
(IgG1) (Coulter Immunology, Hialeah, FL); anti-
 
 
 
4 integrin
(CD49d), HP2/1 (IgG1) (Immunotech, Marseille, France); anti-
 
 
 
5
integrin (CD49e), SAM-1 (IgG2b) (40) (a gift from A. Sonnen-
berg, NKI, Amsterdam, The Netherlands); anti-
 
 
 
4
 
 
 
7, Act-1
(IgG1) (41) (a gift from A. Lazarovits, University of Western On-
tario, London, Canada); anti-ICAM-1 (CD54), RR1/1 (IgG1)
(42) (a gift from T. Springer, Harvard University, Boston, MA);
anti-HGF/SF, 24612.111 (IgG1) (R&D Systems, Abingdon, UK);
anti-CD3, OKT-3 (IgG2a) (ATCC); anti-DRC-1, R4/23 (IgM)
(DAKO, Glostrup, Denmark); anti-CD19, HD37 (IgG1) (DAKO);
and anti-phosphotyrosine, PY-20 (IgG2b) (Affiniti, Nottingham,
UK). Polyclonal antibodies used were rabbit anti–c-Met, C-12
(IgG) (Santa Cruz Biotechnology, Santa Cruz, CA); goat anti-HGF/
SF (R&D Systems); FITC-conjugated rabbit anti-IgD (DAKO);
RPE-conjugated goat anti–mouse (Southern Biotechnology, Bir-
mingham, AL); AP-conjugated goat anti–mouse (total, IgG1, or
IgG2a) (Southern Biotechnology); biotin-conjugated rabbit anti–
mouse (DAKO); biotin-conjugated goat anti–mouse (DAKO);
biotin-conjugated rabbit anti–goat (Vector Laboratories, Burlin-
game, CA); HRP-conjugated goat anti–rabbit (DAKO); and HRP-
conjugated goat anti–rabbit (DAKO). In addition we used a rat
monoclonal anti-CD77, 38.13 (IgM) (43) (provided by J. Wiels,
Institute Gustave-Roussy, Villejuif, France); and RPE-Cy5-con-
jugated streptavidin (DAKO).
 
Cell Lines.
 
The epidermoid carcinoma cell line A431, the
lung fibroblast cell line MRC-5, and the B cell lines Raji, Namalwa,
Daudi, Ramos, JY, and Nalm-6 were obtained from ATCC and
cultured in RPMI 1640 (Gibco BRL/Life Technologies, Paisley,
UK) supplemented with 10% FCS (Integro, Zaandam, The Neth-
erlands). The Burkitt’s lymphoma line EB4B (44) was provided
by R. Jefferis (University of Birmingham, Edgbaston, UK) and
cultured in 10% FCS/RPMI 1640.
 
B Cell Isolation and Culturing.
 
B cells were isolated as de-
scribed previously (29). Total B cell fractions were 
 
 
 
97% pure as
determined by FACS
 

 
 analysis.
B cells were cultured in Iscove’s medium (Gibco BRL/Life
Technologies) containing 10% FCS, 0.5% BSA, 50 
 
 
 
g/ml human
transferrin (Sigma, Bornem, Belgium) and 5 
 
 
 
g/ml bovine pan-
creas insulin (Sigma). Some media were supplemented with 50
ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma).
For CD40 ligation, B cells were cultured on irradiated (7,000
rad) CD40L-transfected or, as a control, wild-type L cells (45) (pro-
vided by J. Banchereau, Schering Plough, Dardilly, France). In spe-
cific experiments, culture media were supplemented with either
pansorbin cells of 
 
Staphylococcus aureus
 
 strain Cowan I (0.002%; Cal-
biochem Novabiochem, La Jolla, CA), rabbit anti–human Ig-
coated beads (2 
 
 
 
g/ml) (BioRad Laboratories, Hercules, CA), re-
combinant human IL-2 (100 U/ml) (Eurocetus, Amsterdam, The
Netherlands), recombinant human Il-4 (100 U/ml) (Genzyme Diag-
nostics, Cambridge, MA), or recombinant human IL-6 (1,000 U/ml)
(CLB, Amsterdam, The Netherlands).
 
T Cell Isolation and Culturing.
 
Tonsillar T cells were isolated
as described for the B cell isolation, except that after the second
Ficoll-Isopaque density gradient centrifugation the pellet was col-
lected, washed, and resuspended in shock medium. The remaining
B cells were removed by using a MACS magnetic cell separator
(Miltenyi Biotec, Bergisch Gladbach, Germany) using anti-CD19.
The T cell fraction was 
 
 
 
98% pure as determined by FACS
 

 
analysis.
 
Stromal Cell Isolation and Culturing.
 
Tonsillar stromal cells were
isolated as described (46). The cells were cultured in 100-mm petri
dishes (Costar, Cambridge, MA) containing 10% FCS/RPMI
1640. After 4 d nonadherend cells were removed.
 
FDC Isolation and Culturing.
 
FDC were isolated as described
(29). The cells were cultured in Iscove’s medium containing 10%
Fetal Clone I serum (HyClone Laboratories, Logan, UT). These
FDC-enriched cell cultures contained 10–15% DRC-1–positive
cells.
 
Transfections.
 
c-Met transfected Namalwa cells (Nam
 
met
 
) were
obtained by electroporating Namalwa cells with the eukaryotic
expression plasmid pA71d containing full-length c-
 
met
 
 cDNA (a
gift from G. Hartmann and E. Gherardi, University of Cam-
bridge, Cambridge, UK). After 2 d in culture, transfectants were
selected in culture medium containing 250 
 
 
 
g/ml hygromicin
(Sigma). c-Met positive cells were sub-cloned by using a FACStar
 
plus
 

 
flow cytometer (Becton Dickinson, Mountain View, CA).
 
Immunoprecipitation and Western Blot Analysis.
 
For analysis of ty-
rosine phosphorylation of the c-Met protein, cells were incubated
overnight in serum-free RPMI 1640. Nam
 
met
 
 or EB4B cells were
incubated in serum-free RPMI 1640 in the presence or absence
of 200 ng/ml HGF/SF (R&D Systems). After 5 min at 37
 
 
 
C the
cells were solubilized in ice-cold 2
 
 
 
 lysis buffer containing 20
mM Tris-HCl (pH 8), 250 mM NaCl, 20% glycerol, 2% NP-40,
20 
 
 
 
g/ml aprotinin (Sigma), 20 
 
 
 
g/ml leupeptin (Sigma), 4 mM
sodium orthovandate (Sigma), 10 mM EDTA, and 10 mM NaF.
After 1 h at 4
 
 
 
C the insoluble nuclear material was removed by
centrifugation at 1 
 
  
 
10
 
4
 
 
 
g
 
 at 4
 
 
 
C for 20 min after which the su-
pernatant was precleared with protein A–Sepharose CL-4B
(Pharmacia Biotech) for 45 min at 4
 
 
 
C. c-Met was precipitated
with rabbit anti–c-Met coupled to protein A–Sepharose at 4
 
 
 
C 
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for at least 2 h. The immune complexes were washed with lysis
buffer and diluted in Laemmli sample buffer containing final con-
centrations of 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glyc-
erol, 100 mM 2-mercaptoethanol (BioRad Laboratories), and
0.001% bromophenol blue. After boiling for 5 min, the samples
were subjected to 8% SDS-PAGE. Western blotting was per-
formed as described previously (48).
For analysis of c-Met in total cell lysates, cells were lysed in 50
mM Tris-HCl (pH 8), 150 mM NaCl, 1% NP-40, 10 
 
 
 
g/ml
aprotinin, 10 
 
 
 
g/ml leupeptin, 1 mM sodium orthovandate, 2 mM
EDTA, and 5 mM NaF for 1 h at 4
 
 
 
C. After centrifugation at
1 
 
 
 
 10
 
4
 
 
 
g
 
 and 4
 
 
 
C for 20 min, the supernatant was diluted in
Laemmli sample buffer, boiled for 5 min and subjected to 8%
SDS-PAGE. Western blotting was performed as described previ-
ously (48).
 
FACS
 

 
 Analysis.
 
Expression of c-Met on tonsillar B cell sub-
populations was studied using a triple staining technique (47).
Staining was measured by using a FACSCalibur
 

 
 flow cytometer
(Becton Dickinson).
 
Immunohistochemistry.
 
Expression of c-Met in tonsillar tissue
was analysed by single and double staining. For single staining
cryostat tonsil sections were fixed in acetone for 10 min, washed
in PBS and preincubated with 10% normal goat serum (Sera Lab,
Sussex, UK) in PBS for 15 min. After incubating with the pri-
mary antibody for 1 h, endogenous peroxidases were blocked with
0.1% NaN
 
3
 
, 0.3% H
 
2
 
O
 
2
 
, PBS for 10 min. Subsequently, the sec-
tions were stained with biotin-conjugated rabbit anti–mouse for
30 min, followed by an incubation with HRP-conjugated avi-
din–biotin complex for 30 min. Substrate was developed with
3,3-amino-9-ethylcarbazole (Sigma) for 
 
 
 
10 min. Tissue sections
were counterstained with Haematoxylin (Merck, Darmstadt,
Germany).
Double staining was performed as described for the single
staining, except that a cocktail of primary antibodies was used,
which was detected by either a cocktail of AP-conjugated goat
anti–mouse and HRP-conjugated goat anti–rabbit, or a cocktail
of AP-conjugated goat anti–mouse IgG2a and HRP-conjugated
goat anti–mouse IgG1. The second color was developed with Fast
Blue BB (Sigma) for 
 
 
 
10 min.
 
Adhesion Assays.
 
96-well flat-bottom plates (Costar) were
coated overnight with 5 
 
 
 
g/ml human fibronectin (CLB) or 0.2
 
 
 
g/ml recombinant human sVCAM-1 (R&D Systems) at 4
 
 
 
C.
After blocking the plates with 4% BSA, RPMI 1640 (2 h at
37
 
 
 
C), B cells that had been pre-incubated with HGF/SF (R&D
Systems), in the presence or absence of monoclonal antibodies,
for 30 min at 37
 
 
 
C, were added. Then, the plates were centri-
fuged (3 min 800 rpm, no brake) and incubated at 37
 
 
 
C for 25
min. After washing the wells, the bound cells were fixed with
10% neutral buffered formalin solution (Sigma) and stained with
Giemsa (Merck). Bound cells were quantified by using a color
CCD camera (Sony) and NIH Image 1.60 software on an Apple
Quadra 840AV.
 
c-Met ELISA.
 
96-well EIA/RIA plates (Costar) were coated
overnight with mouse anti- HGF/SF immunoglobulins at 4
 
 
 
C.
Then, the plates were washed and blocked with 4% BSA, PBS for
1 h at 37
 
 
 
C. Next, the wells were incubated with culture super-
natants or with a HGF/SF concentration series for 2 h at 37
 
 
 
C,
followed by an incubation with goat anti–c-Met immunoglobu-
lins for 1 h at 37
 
 
 
C. Subsequently, the wells were incubated with
biotin-conjugated rabbit anti–goat immunoglobulins for 60 min
at 37
 
 
 
C followed by HRP-conjugated avidin–biotin complex
(DAKO) for 1 h at 37
 
 
 
C. Substrate was developed with 1,2-phen-
ylenediamine (Fluka Chemica, Buchs, Switzerland) in 50 mM
KH
 
2
 
PO
 
4
 
, 50 mM Na
 
2
 
HPO
 
4
 
 
 
2H
 
2
 
O (pH 5.4) containing H
 
2
 
O
 
2
 
.
The reaction was stopped with 1 N H
 
2
 
SO
 
4
 
 and the results were
analysed at 492 nm using a microplate reader (BioRad Laborato-
ries).
 
RNA Isolation and RT-PCR.
 
Total RNA was isolated with
RNAsol (Cinna/Biotex Laboratories, Houston, TX) according to
manufacturers description. First-strand cDNA synthesis was per-
formed on total RNA by a standard reverse transcription reac-
tion, using Moloney leukemia virus reverse transcriptase (Gibco
BRL/Life Technologies) and p(dN)
 
6
 
 random hexamers (Pharma-
cia Biotech). PCR was performed with Taq DNA Polymerase
(Gibco BRL/Life Technologies), 200 
 
 
 
M dNTPs (Pharmacia Bio-
tech) and 1.5 mM MgCl
 
2
 
 in 1
 
 
 
 PCR Buffer (both Gibco BRL/
Life Technologies). Primers used were HGF-1 (5
 
 
 
-CGACAGTGT-
TTCCCTTCTCG-3
 
 
 
) in combination with HGF-3 (5
 
 
 
-GGT-
GGGTGCAGACACAC-3
 
 
 
), or 5
 
  
 
2M (5
 
 
 
-ATCCAG CGTACT-
CCAAAGATT-3
 
 
 
) in combination with 3
 
  
 
2M (5
 
 
 
-CATGTC-
TCGATCCCACTTAAC-3
 
 
 
). PCR was started with a 5 min
denaturation step at 95
 
 
 
C, after which amplification was per-
formed in 35 cycles of denaturation at 95
 
 
 
C for 30 s, annealing at
60
 
 
 
C for 1 min and elongation at 72
 
 
 
C for 2 min. After a final
elongation step for 10 min at 72
 
 
 
C, samples were cooled on ice
and analysed by electrophoresis in a 1.5% agarose TBE gel con-
taining ethidium bromide.
 
Results
 
The c-Met Receptor Tyrosine Kinase Is Expressed by Activated
Human Tonsillar B Cells as well as by Several B Cell Lines.
 
Expression of c-Met by human tonsillar B cells and by a
panel of B cell lines was assessed by Western blotting and
by FACS
 

 
 analysis. On Western blot, c-Met expression
Figure 1. c-Met expression on
human B cells. (A) PMA induces
c-Met expression on tonsillar B
cells. (B) Several B cell lines con-
stitutively express c-Met. A431
(positive control) is an epider-
moid carcinoma cell line. Raji,
EB4B and Namalwa (Namwt) are
Burkitt’s lymphoma cell lines.
Nammet are c-Met–transfected
Namalwa cells. In both A and B
the Western blot of the cell ly-
sates was stained with anti–c-Met.
The c-Met precursor (pre–c-Met)
and c-Met   chain (c-Met (  ))
are indicated.2124 The c-Met Pathway in B Cell Differentiation
was hardly detectable in freshly isolated tonsillar B cells, but
we observed a strong induction of c-Met (and the c-Met
precursor [pre c-Met]) upon stimulation with the phorbol-
ester PMA (Fig. 1 A). Furthermore, constitutive expression
of c-Met was found in the Burkitt’s lymphoma cell lines
Raji and EB4B, but not in the Burkitt’s lymphoma cell line
Namalwa (Fig. 1 B) nor in the B cell lines Daudi, Ramos,
JY, or Nalm-6 (data not shown). As positive controls, c-Met
expression of the epidermoid carcinoma cell line A431 and
of Namalwa cells stably transfected with c-Met (Nammet)
are shown (Fig. 1 B).
The c-Met Receptor on B Cells Is Functional. The above find-
ings clearly show that B cells can express c-Met and, hence,
might potentially be triggered via the HGF/SF–c-Met
pathway. To demonstrate that the c-Met receptor on B
cells can indeed be functionally activated by HGF/SF, we
studied c-Met receptor phosphorylation on tyrosine resi-
dues in response to HGF/SF. As is shown in Fig. 2, HGF/
SF stimulation of EB4B cells as well as of Nammet B cells re-
sulted in an enhanced tyrosine phosphorylation of c-Met.
This indicates that the HGF/SF–c-Met pathway on B cells
is capable of signaling.
c-Met Receptor Expression on Human Tonsillar B Cell Sub-
sets. To investigate whether c-Met induction is a physio-
logical phenomenon, that occurs also during antigen-specific
B cell differentiation in vivo, we assessed the expression of
c-Met on human tonsillar B cell subsets using FACS triple
staining. The subsets studied, recently defined by Pascual et al.
(13), were: the naive B cell subset, IgD CD38  (Bm1-2);
two GC B cell subsets, IgD CD38 CD77  centroblasts
(Bm3), and IgD CD38 CD77  centrocytes (Bm4); and an
IgD CD38  memory B cell subset (Bm5). Fig. 3 shows
that c-Met is expressed by CD38 CD77  centroblasts (Bm3)
and by a part of the CD38 CD77  subset. This finding is
supported by immunohistochemical studies on frozen sec-
tions of human tonsillar tissue: as is shown in Fig. 4, c-Met
is predominantly expressed by lymphocytes within the dark
zone of the GC, which contains rapidly dividing centro-
blasts and low numbers of FDC. These results mean that
c-Met induction in vivo, occurs in GC-cells at a pre-selec-
tion stage, i.e., cells that have recently been recruited by
antigen plus antigen-specific T lymphocytes in the T cell–
rich extrafollicular microenvironment.
CD40 Ligation Induces a Transient Expression of c-Met on
Tonsillar B Cells. Ligation of the B cell antigen receptor
(BCR) and CD40 plays a key role in the initiation of a T
Figure 2. Tyrosine phosphorylation of c-Met on B cells in response to
HGF/SF. c-Met on EB4B and Nammet B cells becomes phosphorylated
on tyrosine residues upon triggering with HGF/SF. c-Met was precipi-
tated with anti–c-Met antibodies and the Western blot was consecutively
stained with anti-phosphotyrosine- or with anti–c-Met antibodies. The
c-Met precursor (pre–c-Met) and c-Met   chain are indicated.
Figure 3. Expression of c-Met on tonsillar B cell subsets. (A) Germinal center (CD38 ) B cells express the c-Met tyrosine kinase, while naive
(IgD CD38 ) and memory (IgD CD38 ) tonsillar B cells are c-Met negative. Tonsillar B cells were triple-stained with anti-CD38, anti-IgD, and either
anti–c-Met (solid line) or control antibodies (dotted line). (B) c-Met is expressed on centroblasts (CD38 CD77 ) and on a subset of CD38 CD77  GC
cells. Tonsillar B cells were triple stained with anti-CD38, anti-CD77, and either anti–c-Met (solid line) or control antibodies (dotted line).2125 van der Voort et al.
cell dependent B cell response and initiates the GC reaction
(1, 49–51). In view of the expression of c-Met on centro-
blasts, i.e., on recent GC immigrants, we hypothesized that
these receptors might also regulate c-Met expression. To
address this hypothesis, the biological conditions for B cell
activation were mimicked in vitro. Tonsillar B cells were
cultured on CD40 ligand (CD40L) transfected L cells or, as
a control, on wild-type L cells, in the presence or absence
of BCR stimuli (anti-Ig antibodies or Staphylococcus aureus
Cowans strain I [SAC]). As is shown in Fig. 5 A, concur-
rent ligation of CD40 and the BCR induced a strong tran-
sient induction of c-Met in human tonsillar B cells, peaking
at 48 h. Single triggering of CD40 also strongly induced
c-Met (Fig. 5 C) but single ligation of the BCR did not in-
duce c-Met expression above control levels (untransfected
L cells and medium alone) (Fig. 5, B and D). In approxi-
mately half of the experiments, concurrent CD40 and
BCR stimulation resulted in a c-Met induction that was
stronger than after CD40 ligation alone, suggesting synergy
between the CD40 and BCR pathways. Stimulation by
various cytokines including IL-2, IL-4, and IL-6 did not
induce c-Met (data not shown).
These data clearly identify CD40-CD40L as a major
pathway for induction of c-Met in B cells.
HGF/SF Induces Integrin-mediated Adhesion of c-Met–posi-
tive B Cells to VCAM-1 and Fibronectin. Cell motility and
morphogenesis, major functions of the c-Met–HGF/SF path-
way, are dependent on tightly controlled cell adhesion. This
prompted us to study whether the c-Met–HGF/SF path-
way might regulate B cell adhesion. Since c-Met–positive
B cells represent a subset of tonsillar B cells that cannot be
readily purified by negative selection procedures, we ad-
dressed this question by using Namalwa cells transfected
with c-met cDNA (Nammet). The expression of c-Met in this
B cell lymphoma line and the wild-type control (Namwt)
are shown in Fig. 1 B. We observed that HGF/SF induces
a strongly augmented adhesion to both vascular cell adhe-
sion molecule 1 (VCAM-1) and fibronectin of c-met trans-
Figure 4. c-Met expression in the human tonsil. (A) Immunohistochemical double-staining for c-Met (blue) and IgD (red). c-Met is expressed by GC
cells and by vascular endothelium (arrows). Prominant IgD expression is present on B cells of the mantle zones. (B) Serial section of A, stained for c-Met
(blue) and CD38 (red). There are virtually no single c-Met–positive (blue) lymphocytes. Part of the GC cell show double staining (pink) (most clearly visi-
ble in the GC at the lower-right of the picture). A and B are not counterstained. (C) Immunohistochemical single-staining for DRC-1 (red) showing the
FDC-network of the GC. The FDC poor area at the left handside represents the GC-darkzone (dz). (D) serial section of C, stained for c-Met (red).
c-Met–positive cells are predominantly present in the GC-darkzone. C and D are counterstained with hematoxylin (blue).2126 The c-Met Pathway in B Cell Differentiation
fected Namalwa B cells (Nammet) (Fig. 6, A and B). This ef-
fect of HGF/SF on B cell adhesion was dose dependent
and was not observed upon stimulation of wild-type Na-
malwa cells (Namwt). An increased adhesion in response to
HGF/SF to both VCAM-1 and fibronectin was also ob-
served with the Burkitt’s lymphoma cell lines Raji and
EB4B (data not shown).
To identify the adhesion receptors on Nammet responsible
for enhanced VCAM-1 and fibronectin binding, antibody
blocking experiments were performed. Nammet expresses
 4 1 and  4 7, which both are receptors for VCAM-1 and
for an alternatively spliced segment (CS-1) of fibronectin,
but expresses no detectable level of the fibronectin receptor
 5 1 (data not shown). We observed that adhesion to
VCAM-1 and fibronectin was completely blocked by mAbs
against both the  4 and  1 integrin chain (Fig. 6, C and
D). Since c-Met stimulation by HGF/SF did not lead to
increased  4 1 expression (and also did not upregulate or
induce  4 7 or  5 1) (data not shown), these results indi-
cate that the c-Met–HGF/SF pathway enhances B cell ad-
hesiveness through activation of the  4 1 integrin.
Tonsillar Stromal Cells Produce High Levels of HGF/SF.
All together, the above data strongly favor a functional role
of the c-Met–HGF/SF pathway in B cell differentiation,
namely in the regulation of B cell adhesiveness. However,
obviously, an in vivo biological role in this process would
require the availability of HGF/SF within the lymphoid
tissue microenvironment. This prompted us to (a) assay
the production of HGF/SF by primary cultures of various
tonsillar cell populations, and (b) study the expression of
HGF/SF mRNA within these cell populations by RT-
PCR. Determinations of HGF/SF production by ELISA
demonstrate that high levels of HGF/SF are produced by
primary cultures of tonsillar stromal cells, including cultures
of FDC-enriched tonsillar cell subfractions (Fig. 7 A). By
contrast, tonsillar T- or B-lymphocytes, cultured in the
presence or absence of various mitogenic stimuli, did not
produce detectable levels of HGF/SF. Consistent with these
results, in RT-PCR studies HGF/SF mRNA was exclu-
sively detectable in tonsillar stromal cells (Fig. 7 B).
Discussion
The products of proto-oncogenes are important regula-
tory molecules that exert a wide range of effects on basic
cellular functions such as the control of cell growth and dif-
ferentiation. The c-met proto-oncogene product is a recep-
tor tyrosine kinase (52, 53) that binds HGF/SF, a mesen-
chymally derived cytokine with pleiotropic biological effects
on proliferation, cell motility and morphogenesis of epithe-
lial, endothelial, and myogenic cells (31–36, 54). More
recently, the c-Met–HGF/SF pathway has also been impli-
cated in the proliferation and differentiation of early hema-
topoietic progenitor cells (55–58) and in monocyte-mac-
rophage differentiation (59). Here, we demonstrate that the
c-Met–HGF/SF pathway is also operative during T cell–
dependent B cell differentiation, where it is involved in the
control of lymphocyte integrin function on B cells, a pro-
cess regulating adhesion and homing of B cells within the
lymphoid microenvironment.
We observed that stimulation of tonsillar B cells with
phorbol ester PMA leads to a rapid c-Met induction (Fig.
1 A). Induction of c-Met expression upon protein kinase C
(PKC) stimulation by phorbol ester has previously also
been reported in epithelial cell lines (60). In addition, we
observed constitutive expression of c-Met on several B cell
lymphoma lines (Fig. 1 B). The c-Met receptor on these B
cell lines is signaling competent, as triggering by HGF/SF
resulted in enhanced tyrosine phosphorylation of c-Met
(Fig. 2). These findings present the first direct evidence for
expression of a functional c-Met receptor on B lympho-
cytes. Indirect evidence for a role of c-Met in B cells has
previously been provided by Delaney et al. (61), who dem-
onstrated that HGF/SF enhances immunoglobulin produc-
Figure 5. Induction of c-Met
expression on tonsillar B cells by
CD40 and BCR ligation. c-Met
expression by tonsillar B cells
cultured on (A) CD40L-trans-
fected L cells plus anti-Ig anti-
bodies; (B) wild-type L cells; (C)
CD40L-transfected L cells; or
(D) wild-type L cells plus anti-Ig
antibodies. Western blots of the
cell lysates were stained with
anti–c-Met antibodies. The c-Met
precursor (pre–c-Met) and the
c-Met   chain (c-Met ( )) are in-
dicated. In the absence of CD40
stimulation (B and D), no viable
B cells were recovered at 96 and
192 h.2127 van der Voort et al.
tion by murine B cells. However, as c-Met expression was
not studied and whole splenocyte cultures were used, indi-
rect effects of HGF/SF were not ruled out. For T cells,
Shaw and colleagues reported that HGF/SF stimulated the
adhesion and migration of the memory subset. However,
these target cells appeared not to express c-Met (62).
One of the key findings of our study is that concurrent
CD40 and BCR ligation induces a strong transient expres-
sion of c-Met on B cells in vitro (Fig. 5). Presumably, BCR
and CD40 mediated signals are also instrumental in the
physiological induction of c-Met. This is suggested by the
fact that c-Met is expressed in vivo on a subset of tonsillar
centroblasts (CD38 CD77 ) (Figs. 3 and 4). Centroblasts
are the offspring of B cells that have recently been activated
at extrafollicular sites by antigen plus accessory signals pro-
vided by antigen-specific T cells (1). These signals critically
involve CD40/CD40L interactions: patients with x-linked
hyper-IgM syndrome (due to mutated and consequently
defective CD40L) do not develop GC and blocking of the
CD40/CD40L pathway in mice leads to complete inhibi-
tion of GC reactions (49–51, 63, 64). Our results strongly
suggest that c-Met induction is directly linked to the ini-
tiation of the B cell immune response. Indeed, we observed
that dual ligation of CD40 and the BCR also induces c-Met
on naive (IgD CD38 ) B cells (our own unpublished ob-
servation).
As both the migratory and morphogenic responses to
HGF/SF are critically dependent on cell adhesion, could
regulation of the c-Met–HGF/SF pathway also have a reg-
ulatory role in B cell adhesion? This idea is supported by
the finding that HGF/SF augments adhesion of c-Met trans-
fected Namalwa B cells as well as the c-Met expressing B
cell lines Raji and EB4B to VCAM-1 and fibronectin (Fig.
6 and data not shown). This HGF/SF induced adhesion was
mediated through activation of the integrin  4 1. Previous
studies from our own and from other laboratories have
shown an important role for  4 1 in GC formation (27–
29). In the GC,  4 1 mediates B cell adhesion to VCAM-1
on FDC, an interaction that regulates the formation of the
microenvironment required for the affinity selection of GC
B cells. Apart from establishing physical contact between B
cells and FDC,  4 1 presumably contributes directly to
Figure 6. The HGF/SF-c-Met pathway regulates  4 1 integrin-mediated adhesion to sVCAM-1 and fibronectin. (A) Effect of HGF/SF on the bind-
ing of c-Met transfected (Nammet) and control (Namwt) B cells to sVCAM-1. (B) Effect of HGF/SF on the binding of Nammet and Namwt B cells to fi-
bronectin. (C) Effect of anti- 1 (4B4), anti- 4 (HP2/1), and anti- 4 7 (Act-1) integrin antibodies on the binding of Nammet B cells to sVCAM-1. (D)
Effect of anti- 1 (4B4), anti- 4 (HP2/1), and anti- 4 7 (Act-1) integrin antibodies on the binding of Nammet B cells to fibronectin. Cells were pre-
incubated with HGF/SF in the presence or absence of anti-integrin monoclonal antibodies. The results are expressed as relative (compared with the con-
trol cells not incubated with HGF/SF) adhesion. Error bars represent the standard deviation of triplicate wells.2128 The c-Met Pathway in B Cell Differentiation
the B cell selection process itself, as signaling through the
 4 1–VCAM-1 pathway costimulates rescue of GC B cells
from apoptosis (6, 29, 47). Furthermore,  4 1 also regu-
lates cell adhesion to fibronectin (65), an important sub-
strate for cell migration.
The above data strongly favor a functional role of the
c-Met–HGF/SF pathway in B cell differentiation, namely
in the regulation of B cell adhesiveness. Obviously, how-
ever, an in vivo biological role in this process requires the
availability of HGF/SF within the lymphoid microenviron-
ment.  Interestingly, we indeed observed production of
high levels of HGF/SF as well as expression of HGF/SF
mRNA by tonsillar stromal cells. In contrast, tonsillar T- or
B-lymphocytes were HGF/SF negative (Fig. 7).
Adhesion regulation is believed to be fundamental to the
control of cell migration and microenvironmental homing
during lymphocyte differentiation. This migration and hom-
ing within tissues, like recruitment from the blood, pre-
sumably is determined by an organized display of adhesive
ligands and regulatory factors, specific for a given microen-
vironment (23). Thusfar, most studies on the regulation of
integrin-mediated adhesion have focussed on cytokines of
the chemokine family (66). Chemokines, which bind to G
protein linked 7-transmembrane serpentine receptors (67,
68), have been shown to mediate chemotaxis and rapid func-
tional activation of leukocyte integrins on myeloid cells, mac-
rophages, and lymphocytes (69–73). HGF/SF belongs to
the family of plasminogen-related growth factors (74), that
also includes macrophage stimulating protein. These mole-
cules, that are structurally unrelated to the chemokines, have
the basic domain organization and mechanism of activation
of the blood proteinase plasminogen, i.e., they are charac-
terized by the presence of a kringle domain(s), an activation
domain, and a serine proteinase domain. Our present data
strongly support a physiological role of HGF/SF in the reg-
ulation of B cell adhesiveness, microenvironmental homing
and in the morphogenesis of the GC. Local production of
HGF/SF has been demonstrated surrounding blood vessels
in inflammation (75, 76), and in this paper we demonstrate
that HGF/SF is produced by FDC-enriched cell popula-
tions. In view of the pleiotropic effects of HGF/SF on
other cell types, HGF/SF may have additional, as yet un-
kown, roles in antigen-specific B cell differentiation. In
particular, cross-talk between integrins and c-Met–signal-
ing pathways triggered by FDC might contribute to B cell
survival (6, 29, 47). Interestingly, like the chemokines,
HGF/SF has a high affinity for heparin, which is present on
cell surfaces and in the ECM in the form of heparan sul-
phate proteoglycans. This heparan sulphate binding limits
diffusion, thus allowing the development of chemotactic
gradients and the localization of proadhesive activity to the
appropriate lymphoid microenvironment (77).
Figure 7. Expression of HGF/SF protein and mRNA by tonsillar stromal cells and lymphocytes. (A) HGF/SF secretion by cultured T cell, B cells,
stromal cells, and FDC enriched tonsillar cells. ELISAs were performed to determine HGF/SF concentrations in the culture media (lower limit of detec-
tion 400 pg/ml). T and B cells were stimulated as indicated. (B) Expression of HGF/SF mRNA in T cells, B cells, tonsillar stromal cells, and, as a positive
control, in the lung fibroblast cell line MRC-5. The RT-PCR was performed on total RNA, a plasmid containing full-length human HGF/SF cDNA
(pHGF/SF), or on water. Primers used were HGF/SF-specific or, as a control,  2-microglobulin specific.
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